A super-trail molecule comprising two trail trimers
US-2024254193-A1 · Aug 1, 2024 · US
Bh3 peptides and methods of use thereof
US2016200786A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016200786-A1 |
| Application number | US-201615073356-A |
| Country | US |
| Kind code | A1 |
| Filing date | Mar 17, 2016 |
| Priority date | Sep 9, 2002 |
| Publication date | Jul 14, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
First claim
Opening claim text (preview).
What is claimed is: 1 . A composition comprising an isolated BH3 peptide of less than or equal to 50 amino acids in length, and a mitochondrion. 2 . The composition of claim 1 , wherein the BH3 peptide is a pro-apoptotic BID-like BH3 peptide. 3 . The composition of claim 2 , wherein the BID-like BH3 peptide includes an amino acid sequence selected from SEQ ID NOs: 1, 2, and 10. 4 . The composition of claim 1 , wherein the BH3 peptide is an anti-anti-apoptotic BAD-like BH3 peptide. 5 . The composition of claim 4 , wherein the BAD-like BH3 peptide includes an amino acid sequence selected from SEQ ID NOs: 3-7 and 11. 6 . The composition of claim 1 , wherein the mitochondrion is isolated from a cell. 7 . The composition of claim 1 , wherein the BH3 peptide is less than or equal to 35 amino acids in length. 8 . The composition of claim 1 , wherein the BH3 peptide is less than or equal to 25 amino acids in length. 9 . The composition of claim 1 , wherein the BH3 peptide is less than or equal to 15 amino acids in length. 10 . The composition of claim 1 , wherein the isolated BH3 peptide is in a complex with a BCL-2 or BCL-XL protein resident on the mitochondrion. 11 . The composition of claim 1 , wherein the isolated BH3 peptide is in a complex with a MCL-1 protein resident on the mitochondrion. 12 . A composition comprising a mitochondrion contacted with an isolated BH3 peptide of less than or equal to 50 amino acids in length. 13 . The composition of claim 12 , wherein the BH3 peptide is a pro-apoptotic BID-like BH3 peptide. 14 . The composition of claim 13 , wherein the BID-like BH3 peptide includes an amino acid sequence selected from SEQ ID NOs: 1, 2, and 10. 15 . The composition of claim 12 , wherein the BH3 peptide is an anti-anti-apoptotic BAD-like BH3 peptide. 16 . The composition of claim 15 , wherein the BAD-like BH3 peptide includes an amino acid sequence selected from SEQ ID NOs: 3-7 and 11. 17 . The composition of claim 12 , wherein the mitochondrion is isolated from a cell. 18 . The composition of claim 12 , wherein the BH3 peptide is less than or equal to 35 amino acids in length. 19 . The composition of claim 12 , wherein the BH3 peptide is less than or equal to 25 amino acids in length. 20 . The composition of claim 12 , wherein the BH3 peptide is less than or equal to 15 amino acids in length. 21 . The composition of claim 12 , wherein the isolated BH3 peptide is in a complex with a BCL-2 or BCL-XL protein resident on the mitochondrion. 22 . The composition of claim 12 , wherein the isolated BH3 peptide is in a complex with a MCL-1 protein resident on the mitochondrion.
Assignees
Inventors
Classifications
containing a transmembrane segment · CPC title
Antineoplastic agents · CPC title
- C07K14/4747Primary
Apoptosis related proteins · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016200786A1 cover?
- The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
- Who is the assignee on this patent?
- Dana Farber Cancer Inst Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K14/4747. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Jul 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).